NEW YORK (GenomeWeb) – ClearLight Diagnostics announced today that it has raised $3.5 million in a Series B financing round.

The round was led by a syndicate of existing investors created by Wiegers Capital Partners.

The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications using the Clarity lipid-clearing technique developed by company founder Karl Deisseroth and his colleagues at Stanford University, coupled with a microscopy method called clarity optimized light-sheet microscopy (COLM).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.